Orphan Drug Pricing: $500K a Year for 200 Patients

A drug for 500 patients is priced at $500,000 a year. How does that become a $250 million drug? Everyone thinks orphan drug pricing is a scandal. For investors, it is a formula. Here is how the math works, why the numbers are what they are, and how to model revenue for a drug targeting a population under 1,000 patients.

The one-sentence answer

Orphan drug pricing is population times price times years on therapy, protected by 7-year market exclusivity and reinforced by priority review vouchers worth $100 million plus. The formula is legible once you know the inputs.

Step 1: Understand the Orphan Drug Act framework

The Orphan Drug Act of 1983 created the legal structure that makes ultra-rare drug development profitable. A drug designated for a disease affecting fewer than 200,000 people in the US receives three benefits:

• 7-year market exclusivity from the date of FDA approval. No competitor can market the same drug for the same orphan indication during this period, even if the patent lapses.
• Tax credits for up to 50% of clinical trial costs.
• Waived FDA filing fees (PDUFA fees are approximately $4 million per application in 2026).

The exclusivity is the key. A standard drug patent gives 20 years of protection from filing, but the patent clock starts before clinical trials, so effective protection after approval is often 10 to 12 years. Orphan exclusivity is 7 years from approval, and it applies even if there is no patent. The FDA maintains the full Orphan Drug Act designation and exclusivity requirements on its rare disease products page. For a full breakdown of how PDUFA fees and review timelines work, see our PDUFA date guide.

Step 2: Learn why pricing is value-based, not cost-plus

Ultra-rare disease drugs are not priced on manufacturing cost. They are priced on value: what insurers and governments will pay for a therapy that changes the trajectory of a devastating disease in a population with no alternatives.

The framework insurers use is cost per QALY (quality-adjusted life year). A QALY represents one year of perfect health. US payers typically reimburse therapies at $100,000 to $300,000 per QALY gained. For a drug that adds 5 QALYs in a fatal disease with no treatment, a price of $500,000 to $1 million per year falls within the accepted range.

That is why $500,000 per year is “normal” for an ultra-rare disease drug. The patient population is tiny, the alternative is no treatment, and the QALY math supports the price. Ionis zilganersen for Alexander disease, with roughly 500 diagnosed cases globally, is expected to launch at $300,000 to $500,000 per patient per year. At 200 US patients and $500,000, that is $100 million in annual revenue. Our zilganersen platform analysis shows why even $100 million does not move Ionis’s $8.9 billion market cap; the value is in the platform validation, not the single drug.

Step 3: Do the patient-population math

The revenue formula for an orphan drug is straightforward:

Diagnosed patients × eligible patients × uptake rate × annual price × years on therapy = peak revenue

Take zilganersen as a worked example. Alexander disease has an estimated prevalence of 1 in 2.7 million people, meaning roughly 500 diagnosed cases worldwide. If Ionis identifies 200 US patients, prices at $500,000 per year, and achieves 80% uptake in the first three years, peak US revenue is 200 × 0.80 × $500,000 = $80 million annually. Add international patients and the total approaches $150 million.

Now take BridgeBio (BBIO) BBP-418 for LGMD2I/R9 muscular dystrophy. LGMD2I/R9 is rarer than DMD but more common than Alexander disease. If BBP-418 reaches 2,000 US patients at a midpoint of $300,000 per year, peak revenue is $600 million. Our BBP-418 PDUFA analysis walks through the math, including the $200,000 to $400,000 pricing range and the 3x peak-sales multiple that supports the pipeline valuation contribution.

The point: the patient count is the lever. A drug for 500 patients at $500,000 generates $250 million. A drug for 2,000 patients at $300,000 generates $600 million. Population matters more than price.

Step 4: Add the Priority Review Voucher bonus

A priority review voucher (PRV) is a transferable FDA coupon that converts a standard 10-month review into a 6-month priority review. Companies that win approval for a rare pediatric disease drug receive a PRV they can sell. Recent sale prices range from $100 million to $180 million.

For a small-cap biotech, PRV cash can exceed the company’s entire market cap. Rocket Pharmaceuticals (RCKT) sold a Rare Pediatric Disease PRV for $180 million in April 2026 after Kresladi approval. That is non-dilutive capital that extends cash runway by quarters or years. For a full breakdown of the four PRV programs, sale price history, and how to trade PRV announcements, see our Priority Review Voucher guide.

BridgeBio’s BBP-418 carries Rare Pediatric Disease designation. If approved on November 27, 2026, BridgeBio qualifies for a PRV worth an estimated $100 million to $150 million. That voucher alone could fund a meaningful chunk of the commercial launch. When modeling orphan drug economics, add the PRV as a one-time cash inflow in year one.

Step 5: Account for one-time curative pricing vs chronic therapy

Gene therapies complicate the pricing math because they are one-time treatments, not chronic therapies. The pricing question becomes: what is a cure worth upfront versus a lifetime of chronic therapy?

The precedent is clear. Novartis priced Zolgensma for spinal muscular atrophy at $2.1 million. Vertex priced Casgevy for sickle cell disease at $2.2 million. Bluebird priced Lyfgenia at $3.1 million. These are one-time doses, but the revenue math is different from chronic orphan drugs.

Casgevy at $2.2 million per patient generated only $42.9 million in Q1 2026 revenue, roughly 20 patients recognized as revenue. Eighteen months after approval, only 39 patients had been infused out of a 60,000-person addressable market. The Casgevy 18-month commercial analysis shows why: apheresis, manufacturing, conditioning chemotherapy, and treatment-center capacity throttle the funnel. For gene therapies, model a 5 to 10 year ramp. For chronic orphan drugs, model a 3 to 5 year ramp.

Step 6: Model the payer concentration problem

Rare disease drugs often have 3 to 5 payers covering 80% of patients. That concentration changes negotiation dynamics. In primary care, a drug has thousands of payers and a payer that excludes it loses market share. In rare disease, a single payer can cover 30% of the eligible population. If that payer refuses to reimburse, the drug loses a third of its revenue.

Outcomes-based agreements are the common compromise. Vertex negotiated contracts for Casgevy where payers pay only if the therapy works over a multi-year horizon. These agreements delay cash flow. When modeling orphan drug revenue, assume a 12 to 24 month lag between infusion and revenue recognition under outcomes-based contracts.

Step 7: Factor in international access

The US accounts for the majority of orphan drug revenue at premium pricing. International markets use different frameworks: NICE cost-effectiveness thresholds in the UK, AMNOG benefit assessments in Germany, generic licensing in low- and middle-income countries.

Gilead’s lenacapavir for HIV pre-exposure prophylaxis is the clearest dual-market model: premium pricing in the US and high-income countries, generic licensing for 120 LMIC countries. For orphan drugs, international contribution is often 20 to 40% of peak revenue. Model it conservatively until pricing agreements are announced.

Common mistakes

• Assuming orphan pricing applies to every rare disease. The Orphan Drug Act threshold is 200,000 patients in the US. Diseases at 199,000 are not ultra-rare.
• Forgetting the PRV. A $100 million to $180 million voucher is a material cash event for a small-cap biotech.
• Modeling gene therapy revenue like a chronic therapy. One-time curative pricing sounds large, but the treatment funnel throttles revenue. Casgevy at $2.2 million per patient generated $42.9 million in a quarter.
• Ignoring payer concentration. Three payers covering 80% of patients means a single denial blocks a third of revenue.
• Assuming the 7-year exclusivity is permanent. It covers the orphan indication only. A competitor can enter with a different drug for the same disease.
• Using peak sales multiples without discounting for ramp. A drug at $600 million peak revenue in year 5 is not worth 3x $600 million today. See our biotech valuation methods guide for the rNPV framework.

Final checklist

• Orphan Drug Act exclusivity confirmed (7 years from approval)
• US prevalence verified from Orphanet or NIH GARD
• Diagnosed patients estimated (diagnosed is always less than prevalence)
• Annual price benchmarked against comparable ultra-rare drugs ($300K-$2M)
• Peak revenue calculated: diagnosed × uptake × price × years
• PRV eligibility checked (Rare Pediatric Disease, Tropical Disease, or Medical Countermeasures)
• Payer coverage mapped (how many payers cover the eligible population)
• International revenue modeled conservatively (20-40% of peak)
• Revenue ramp timeline set (3-5 years for chronic, 5-10 years for gene therapy)